FUNDINFO
UBS AG and its group company Fondcenter AG have commissioned fundinfo AG to procure and source fund data from fund providers and asset managers. In order to provide efficient, legally compliant investment advice, UBS Fondcenter's external and internal partners require on-demand access to complete, accurate and up-to-date fund information, including MiFID II and PRIIPs data. They also rely on the openfunds standard for fund data that was launched and is being continuously enhanced by UBS Fondcenter, Credit Suisse and Julius Bär.
"fundinfo has many years of experience in the procurement, validation and distribution of fund information and meets our high quality requirements", says Christophe Hefti, head UBS Fondcenter at UBS Asset Management. "By partnering with fundinfo, we can concentrate on our core competencies and expand our range of services, including data preparation. At the same time, we are providing fund providers with an experienced partner for high-quality fund data and document management."
“After working successfully with UBS Fondcenter for many years in the area of fund document management, we are pleased and proud that UBS Fondcenter has now placed their trust in fundinfo to perform their fund data management” says Jan Giller, Head of Sales & Marketing at fundinfo. "It is a privilege and a strong testament to our capabilities that the largest asset manager in Switzerland has chosen to work with fundinfo to procure their fund data".
Fund providers are requested to ensure that their static fund data is provided correctly and promptly to fundinfo according to the openfunds data standard (www.openfunds.org ). The openfunds standard was initiated by the fund and banking industries. Currently the openfunds Association has 48 active and informational members. Information about fundinfo’s Data Dissemination Service can be found by visiting about.fundinfo.com , or clicking on this short video .
About fundinfo AG
fundinfo AG hosts one of the leading international platforms for information and mandatory publications of investment funds. The platform www.fundinfo.com strengthens the network between fund houses, fund distributors and investors and is recognised by financial market supervisory authorities for mandatory publications. The service is available in Europe and Asia, and covers thousands of funds from the world’s largest fund houses. Founded in 2005 and headquartered in Zürich, Switzerland, fundinfo AG has offices in Berlin, Frankfurt, Hong Kong, London, Madrid, Paris and Singapore.
About Fondcenter AG
Fondcenter AG, a group company of UBS AG, is the leading fund platform in Switzerland and one of the most important in Europe and Asia. Since 1993, UBS Fondcenter has brought together around 300 distribution partners – mainly banks, insurance companies and regulated financial institutions from Switzerland, Europe and Asia – with around 400 fund providers. In addition to its head office in Zurich, UBS Fondcenter now has new offices in Frankfurt and Hong Kong.
Photos and logos: https://about.fundinfo.com/en/news/photos-and-logos/
View source version on businesswire.com: http://www.businesswire.com/news/home/20171204005801/en/
Contact:
fundinfo AG
Diana Mampell, Marketing Manager
Email: diana.mampell@fundinfo.com
Tel.
+41 44 286 91 01
Web: http://about.fundinfo.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom